MedTrace Logo

Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer

NCT05652283 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2024-11-27

No results posted yet for this study

Summary

The goal of this type of clinical trial study is to evaluate the safety and efficacy of Pamiparib combined with Surufatinib as a new neoadjuvant therapy in newly diagnosed patients with advanced ovarian cancer.

Conditions

Interventions

DRUG

Pamiparib

Pamiparib capsule 40 mg/time, twice a day, oral, 3 weeks as a cycle, 3 cycles

DRUG

Surufatinib

Surufatinib 250 mg/time, once a day, oral, 3 weeks as a cycle, 2 cycles

Sponsors & Collaborators

  • Bai-Rong Xia

    lead OTHER

Principal Investigators

  • Bai-Rong Xia, MD · Anhui Provincial Cancer Hospital

  • Wenjing Jiang · Anhui Provincial Cancer Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-06
Primary Completion
2024-05-31
Completion
2026-05-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05652283 on ClinicalTrials.gov